We want to share an important 2026 update regarding GLP-1 medications (Ozempic®, Wegovy®, Mounjaro®, and Zepbound®). Insurance carriers are requiring significantly more prior authorizations (PA)—and we are seeing more denials than in prior years.

If you’ve been told you have a “fatty liver” or the newer term MASH (metabolic dysfunction–associated steatohepatitis), you’re not alone—and you’re not stuck. MASH is rising fast alongside weight gain, insulin resistance, and type 2 diabetes. For years, everyday advice—lose weight, move more, watch carbs—was the only path forward. Important, yes, but often not enough. Now, there’s a game-changer: semaglutide (Wegovy) has received FDA approval to treat MASH with liver fibrosis, giving primary care teams and patients a powerful new option alongside nutrition, movement, and metabolic care.

Did you know that 1 in 3 adults in the U.S. has metabolic syndrome, yet most don’t even know it? This cluster of risk factors silently increases your chances of developing heart disease, diabetes, and stroke. But here’s the good news: with the right strategies, you can reverse the course and reclaim control of your health.